Be a part of a new era in cellular therapy for the potential treatment of solid-tumor cancers

Many advancements have been made in the treatment of cancer, including a recent focus to develop treatments that activate the immune system to fight cancer, called immunotherapies.

Despite this progress, existing immunotherapies are effective in a relatively small number of patients and types of cancer. Furthermore, in some cases even when therapies are initially effective, the disease eventually no longer responds to treatment and progresses. For the treatment of cancer, Rubius Therapeutics is creating engineered red blood cells with cancer-fighting proteins on the cells’ surface to mimic how the immune system naturally functions to fight cancer. These Red Cell Therapeutics™ have the potential to extend the benefits of immunotherapy to a larger number of patients and in more types of cancers.

Rubius Therapeutics is developing an investigational potential cancer treatment option for patients with solid tumors, or cancers of the organs called RTX-240. RTX-240 is an investigational cellular therapy, which is an engineered red blood cell that is designed to replicate how the immune system functions in order to generate an immune response against cancer.

About RTX-240
RTX-240 is an investigational cellular therapy that aims to activate the immune system to fight cancer.

RTX-240 is an engineered red blood cell that is being evaluated in a Phase 1/2 clinical trial for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

RTX-240 is an investigational cellular therapy that is designed to activate and amplify the effects of immune system cells called natural killer (NK) cells and T cells, which play a role in killing tumor cells. The Phase 1/2 clinical study of RTX-240 has three separate Phase 1 arms – an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors, an ongoing monotherapy dose escalation arm in adults with relapsed/refractory acute myeloid leukemia, and combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors.

Learn more about RTX-240